177 related articles for article (PubMed ID: 12022712)
1. Future drugs for the treatment of benign prostatic hyperplasia.
Andersson KE; Chapple CR; Höfner K
World J Urol; 2002 Apr; 19(6):436-42. PubMed ID: 12022712
[TBL] [Abstract][Full Text] [Related]
2. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists.
Andersson KE
World J Urol; 2002 Apr; 19(6):390-6. PubMed ID: 12022707
[TBL] [Abstract][Full Text] [Related]
3. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
Carson CC
BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
5. Benign prostatic hyperplasia - progress in pathophysiology and management.
Dobrek Ł; Thor PJ
Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
[TBL] [Abstract][Full Text] [Related]
6. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
Schulman CC
Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
Chapple CR
BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
[TBL] [Abstract][Full Text] [Related]
8. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
Trachtenberg J
BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
10. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
12. LUTS treatment: future treatment options.
Andersson KE
Neurourol Urodyn; 2007 Oct; 26(6 Suppl):934-47. PubMed ID: 17696154
[TBL] [Abstract][Full Text] [Related]
13. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
Nickel JC
Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
[TBL] [Abstract][Full Text] [Related]
15. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
[TBL] [Abstract][Full Text] [Related]
16. Translational pharmacology in aging men with benign prostatic hyperplasia: molecular and clinical approaches to alpha1-adrenoceptors.
Kojima Y; Kubota Y; Sasaki S; Hayashi Y; Kohri K
Curr Aging Sci; 2009 Dec; 2(3):223-39. PubMed ID: 20021417
[TBL] [Abstract][Full Text] [Related]
17. α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists.
Andersson KE
World J Urol; 2002 Apr; 19(6):390-396. PubMed ID: 28386659
[TBL] [Abstract][Full Text] [Related]
18. Comorbid LUTS and erectile dysfunction: optimizing their management.
Kaminetsky J
Curr Med Res Opin; 2006 Dec; 22(12):2497-506. PubMed ID: 17265598
[TBL] [Abstract][Full Text] [Related]
19. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
20. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
Kulig K; Malawska B
Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
